Novartis and Bristol Myers Squibb have inadvertently set a new precedent for transparency as they navigate the complex safety challenges of applying oncology tools to chronic autoimmune diseases. This strategic pivot reflects a broader industry realization that the risk-benefit calculus for
Traditional views of Information Technology as an ancillary back-office function are being rejected in favor of a clinical care model. The healthcare sector has reached a tipping point where a network failure is now as critical as a power outage in an intensive care unit. Recent breaches at
Documentation such as bank statements or receipts is required for those seeking to recover up to $500 in ordinary expenses related to credit monitoring and identity fees. This requirement stems from the final resolution of a class-action lawsuit against the Fort Wayne Medical Education Program
Recent setbacks in autoimmune trials have prompted a return to more established, well-validated manufacturing standards to ensure long-term patient stability. While the initial migration of Chimeric Antigen Receptor T-cell therapy from liquid tumors to refractory autoimmune diseases sparked immense
The FTC's complaint details how users were allegedly billed for prescription subscriptions almost instantly, often before a licensed healthcare professional had even reviewed their medical intake forms. This aggressive legal action, filed in July 2026, represents a coordinated effort by the Federal
Regulatory bodies like the FDA will likely demand more detailed pharmacokinetic characterization of tissue distribution following the prolonged activity seen with Kylo-11. The cardiovascular research community is currently absorbing the profound implications of the Phase 1 clinical trial results
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64
